Skye Bioscience Inc expected to post a loss of 28 cents a share - Earnings Preview
18/03/2025 20:25
Skye Bioscience Inc SKYE.OQ SKYE.O is expected to show no change in quarterly revenue when it reports results on March 20 for the period ending December 31 2024 LSEG's mean analyst estimate for Skye Bioscience Inc is for a loss of 28 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for Skye Bioscience Inc is $18.00, above its last closing price of $2.53. Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Sep. 30 2024 | -0.25 | -0.25 | -0.10 | Beat | 60.1 |
| Jun. 30 2024 | -0.21 | -0.19 | -0.20 | Missed | -2.6 |
| Mar. 31 2024 | -0.16 | -0.16 | -0.18 | Missed | -12.5 |
| Dec. 31 2023 | -0.38 | -0.38 | -0.63 | Missed | -65.8 |
| | |||||
| |
Recent news on Skye Bioscience
See all newsBrief: Skye Announces Cohort Review Committee Approved Opening Of Cohort 2 Based On Favorable Safety Data From First Four Participants Treated In Cohort 1
U.S. RESEARCH ROUNDUP-Accuray, Aevex, Zoetis
U.S. STOCKS ON THE MOVE-Tesla, Blue Owl, Ford
U.S. STOCKS ON THE MOVE-Energy firms, Estee Lauder, HMH Holding
Skye Bioscience rises as it begins testing higher doses of obesity drug